|2.||Coronary Artery Disease (Coronary Atherosclerosis)
|3.||Cardiac Arrhythmias (Arrythmia)
|4.||Cardiomegaly (Heart Hypertrophy)
|1.||Cheng, Ke: 4 articles (02/2014 - 03/2012)|
|2.||Marbán, Eduardo: 4 articles (02/2014 - 03/2012)|
|3.||Marbán, Linda: 4 articles (02/2014 - 03/2012)|
|4.||Malliaras, Konstantinos: 4 articles (02/2014 - 03/2012)|
|5.||Rabkin, David G: 4 articles (12/2013 - 06/2003)|
|6.||Gelpi, Ricardo J: 4 articles (09/2012 - 05/2005)|
|7.||D'Annunzio, Verónica: 4 articles (09/2012 - 05/2005)|
|8.||Shernan, Stanton K: 4 articles (01/2011 - 08/2008)|
|9.||Liu, Kuang-Yu: 4 articles (01/2011 - 08/2008)|
|10.||Body, Simon C: 4 articles (01/2011 - 08/2008)|
|1.||Milrinone (Primacor)FDA LinkGeneric
09/01/1994 - "Milrinone is a phosphodiesterase inhibitor with positive inotropic and vasodilator effects that are useful in the treatment of ventricular dysfunction after cardiac surgery. "
12/01/2015 - "Milrinone is an inotropic agent with vasodilating properties used in the treatment of ventricular dysfunction. "
01/01/2010 - "In this study, we evaluate the effect of milrinone on patients with ventricular dysfunction undergoing coronary artery bypass graft (CABG). "
09/01/2010 - "Inodilator milrinone is commonly used intravenously for patients with pulmonary hypertension and ventricular dysfunction in cardiac surgery. "
04/01/1998 - "Amrinone and milrinone are phosphodiesterase inhibitors with positive inotropic effects useful for the treatment of ventricular dysfunction after cardiac surgery. "
01/01/1999 - "Despite the documented efficacy of cardiac glycosides in improving symptoms in patients with heart failure caused by systolic ventricular dysfunction, considerable debate continues as to whether the use of this class of drugs should continue into the next millennium. "
10/01/1993 - "Although supported by 2 centuries of anecdotal clinical evidence, the safety and efficacy of the cardiac glycosides for the treatment of congestive heart failure due to systolic ventricular dysfunction had never been rigorously examined by prospective clinical trials until the past decade. "
03/09/1999 - "Moreover, despite the fact that the molecular target for the cardiac glycosides, the alpha-subunit of sarcolemmal Na+K+-ATPase (or sodium pump) found on most eukaryotic cell membranes, has been known for several decades, it remains controversial whether the sympatholytic or positive inotropic effects of these agents is the mechanism most relevant to relief of heart failure symptoms in humans with systolic ventricular dysfunction. "
11/01/2006 - "Clinical studies proved the efficacy of ivabradine in patients with stable angina, while clinical data are awaited to verify its probable value in the treatment of atrial tachyarrhythmias and tachycardia due to ventricular dysfunction. "
07/01/2010 - "Efficacy of ivabradine in a case of inappropriate sinus tachycardia and ventricular dysfunction."
|4.||Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA
03/01/2004 - "The ongoing large controlled, double blind, randomized trials will provide an important information concerning the efficacy of ACE inhibitors to prevent progression of ventricular dysfunction in paediatric oncologic patients."
01/01/2003 - "Description of adverse events in reports of randomised clinical trials of ACE inhibitors in CHF or ventricular dysfunction was examined, and a meta-analysis was performed. "
05/01/1994 - "The role and use of ACE inhibitors in patients with chronic systolic ventricular dysfunction, established in earlier trials, has been further clarified. "
10/01/2015 - "Medications including angiotensin-converting enzyme inhibitors and β-blockers are used to treat ventricular dysfunction, despite limited evidence of their efficacy in this population. "
06/01/2002 - "The prescription of angiotensin converting enzyme inhibitors prescription to patients with ventricular dysfunction increased with the severity of ventricular dysfunction and was more frequent in patients admitted to the cardiology department. "
|5.||Brain Natriuretic Peptide (Natrecor)FDA Link
03/01/2006 - "Plasma brain natriuretic peptide (BNP) levels have a high predictive value for excluding patients with ventricular dysfunction and therefore could serve as a marker for identifying patients who demonstrate improved LV function. "
01/01/2000 - "The purpose of this study was to evaluate the significance of brain natriuretic peptide (BNP) in the diagnosis of HF with systolic or isolated diastolic ventricular dysfunction. "
08/01/2014 - "By day 3, B-type natriuretic peptide in the range of ventricular dysfunction was identified. "
03/01/2014 - "N-terminal pro-B-type natriuretic peptide levels >128 pg/mL at 20-week gestation, the presence of a mechanical valve, and subpulmonary ventricular dysfunction before conception were independently associated with events [odds ratio (OR) 10.6 (P = 0.039), OR 12.0 (P = 0.016), and OR 4.2 (P = 0.041), respectively]. "
05/01/2013 - "Concentrations of B-type natriuretic peptide (BNP) are recognised as a reliable marker of ventricular dysfunction in adults. "
|6.||carvedilol (Coreg)FDA LinkGeneric
08/01/2010 - "Echocardiographic evaluation of children with systemic ventricular dysfunction treated with carvedilol."
05/01/2006 - "Prospective single-arm protocol of carvedilol in children with ventricular dysfunction."
07/01/2013 - "Children receiving carvedilol for treatment of dilated cardiomyopathy with moderate to severe ventricular dysfunction were included into the study. "
03/15/2005 - "Carvedilol is known to decrease the severity of ventricular dysfunction, to increase the left ventricular ejection fraction (LVEF), and, consequently, to reduce morbidity and mortality in patients with dilated cardiomyopathy. "
01/01/2002 - "However, a multicenter, randomized controlled trial to evaluate carvedilol in pediatric heart failure from systolic ventricular dysfunction is currently ongoing and should help to clarify the efficacy and tolerability of carvedilol in children."
|7.||TNFR-Fc fusion protein (etanercept)FDA Link
05/01/2007 - "In animal models and small-scale clinical trials, anti-TNF therapy showed some promise in treating chronic heart failure, whereas larger, multicenter, randomized, placebo-controlled clinical trials (i.e., RECOVER [Research into Etanercept Cytokine Antagonism in Ventricular Dysfunction] and RENAISSANCE [Randomized Etanercept North American Strategy to Study Antagonism of Cytokines]) failed to show a statistically significant difference in composite clinical function score for anti-TNF therapy versus placebo. "
08/01/2008 - "We measured baseline blood serum collagen (amino-terminal propeptide of collagen III [PIIINP], metalloproteinase 1 [MMP-1], tissue inhibitor of metalloproteinase 1 [TIMP-1]), and inflammatory (high-sensitivity C-reactive protein [(hsCRP], interleukin [IL]-18, IL-10) markers in 1009 patients enrolled in the Research into Etanercept Cytokine Antagonism in Ventricular Dysfunction (RECOVER) trial. "
|8.||pro-brain natriuretic peptide (1-76)IBA
10/30/2013 - "Combining NT-proBNP and HF risk factors may identify those with ventricular dysfunction. "
06/01/2013 - "Levels of NT-proBNP positively correlated with atrioventricular valve regurgitation (r = 0.29, P = 0.013) and ventricular dysfunction (r = 0.23, P = 0.052) only in patients with TCPC, but not in patients with APC or AVC (r = 0.01, P = 0.509 and r = 0.10, P = 0.493, respectively). "
04/01/2013 - "Nt-proBNP is a valuable marker of ventricular dysfunction. "
01/01/2013 - "Ang-2 correlates with NYHA class and ventricular dysfunction comparable to NT-proBNP. "
02/01/2012 - "Compared to shunt defects nt-proBNP concentrations were significantly higher in left or right ventricular outflow tract obstruction with intact ventricular septum (mean 15,639 ng/L (range 2,301-42,479 ng/L) vs. 3,891 ng/L (595-13,752 ng/L), p = 0.013), and corresponded to the degree of ventricular dysfunction. "
11/01/2001 - "Particular attention was given to factors that are responsible for exaggerated myocardial deposition of collagen that, by itself, may be responsible for ventricular dysfunction and impaired coronary hemodynamics in hypertensive and aging hearts. "
12/01/1990 - "It is possible that excess collagen is intimately involved with diastolic ventricular dysfunction, but that this may be a reversible process if the collagen-producing stimulus is removed. "
01/01/1987 - "A better understanding of the dynamic behavior of the collagen matrix may offer new insights into the pathogenesis of ventricular dysfunction that accompanies the chronic pressure-overloaded state."
07/01/2001 - "The progressive accumulation of interstitial collagen fibers in both chronic cardiac diseases may be expected to decrease myocardial compliance and disrupt synchronous contractions of the ventricles during systole, contributing to a spectrum of ventricular dysfunction that involve either the diastolic or systolic phase of the cardiac cycle or both. "
09/30/1998 - "The accumulation of interstitial collagen fibers in chronic chagasic myocarditis may be expected to decrease myocardial compliance and disrupt synchronous contraction of the ventricles during systole, contributing to a spectrum of ventricular dysfunction that involve either the diastolic or systolic phase of the cardiac cycle or both. "
05/01/2005 - "These data provide further evidence that primary asynchrony is not only a marker of chronic ischemic ventricular dysfunction, but is associated with a modified contraction pattern in which normal oxygen tension coexists with reduced perfusion."
12/21/2004 - "Oxygen deprivation for prolonged periods of time provokes cardiac cell death and ventricular dysfunction. "
01/01/2000 - "Oxygen deprivation for prolonged periods leads to cardiac cell death and ventricular dysfunction. "
03/01/1993 - "Although oxygen free radical production is thought to occur only early during postischemic reflow, the use of oxygen radical scavengers in a model of regional stunning was shown to attenuate the ventricular dysfunction."
10/01/1983 - "When guidelines for patient selection and dosing are adhered to, ventricular dysfunction and cardiac decompensation secondary to atherosclerotic occlusive coronary artery disease can be improved without adversely affecting the myocardial oxygen supply and demand balance. "
|1.||Cardiac Resynchronization Therapy
12/20/2005 - "Cardiac resynchronization therapy has been shown to be an effective treatment for patients with systolic ventricular dysfunction, prolonged (>120 ms) QRS duration, and New York Heart Association (NYHA) functional class III or IV symptoms despite optimal medical therapy. "
11/01/2014 - "Cardiac resynchronization therapy is associated with improved quality of life and reduced morbidity and mortality in patients with severe ventricular dysfunction and wide QRS. "
11/01/2014 - "Progressive ventricular dysfunction among nonresponders to cardiac resynchronization therapy: baseline predictors and associated clinical outcomes."
11/01/2014 - "Successful Fontan conversion combined with cardiac resynchronization therapy for a case of failing Fontan circulation with ventricular dysfunction."
01/01/2014 - "In children with systemic LV and RV pacing-induced ventricular dysfunction, a conversion to LV apex pacing was an attractive alternative to cardiac resynchronization therapy."
01/01/1991 - "Twenty patients who had undergone a heterotopic heart transplant were studied prospectively to determine the relationship between rejection and ventricular dysfunction assessed from gated blood-pool studies. "
09/10/2013 - "Ventricular dysfunction adversely affects transplant-free survival and atrioventricular valve function. "
09/10/2013 - "Interstage transplant-free survival, ventricular dysfunction, and AVVR were equivalent among palliation strategies. "
09/10/2013 - "We sought to compare these strategies to understand longitudinal differences in interstage ventricular dysfunction and their subsequent impact on transplant-free survival and atrioventricular valve regurgitation (AVVR) as well as the relationship between adverse events and ventricular function. "
10/01/2011 - "Univariable competing risk analyses showed atrioventricular valve regurgitation (AVVR) >mild, age ≤ 3 months at BDG, ventricular dysfunction >mild, and prolonged hospital stay after S1P to be associated with increased risk of death or orthotopic heart transplant. "
|3.||Coronary Artery Bypass (Coronary Artery Bypass Surgery)
04/01/2009 - "Ventricular dysfunction (VnD) after primary coronary artery bypass grafting is associated with increased hospital stay and mortality. "
04/01/2009 - "Natriuretic peptide system gene variants are associated with ventricular dysfunction after coronary artery bypass grafting."
08/01/2008 - "Ventricular dysfunction was defined as requirement for at least two inotropes or new intra-aortic balloon pump or ventricular assist device support after coronary artery bypass grafting. "
01/01/2001 - "Coronary artery bypass grafting is frequently the only therapeutic option, but ventricular dysfunction is generally considered to be a risk factor. "
01/01/1998 - "Patients with severe ventricular dysfunction make up a special subset of patients who undergo coronary artery bypass procedures. "
|4.||Transplantation (Transplant Recipients)
07/01/1990 - "Nuclear medicine studies play an important role in evaluating potential transplant recipients and in providing documentation of the severity of ventricular dysfunction and the presence of ischemic but viable myocardium. "
10/01/2015 - "Primary transplantation in infancy is selectively recommended for severe systemic ventricular dysfunction, severe atrioventricular valve insufficiency, and occlusive coronary artery anomalies, particularly with single ventricle physiology. "
04/01/2011 - "We report on a female patient, diagnosed with humoral rejection, leading to severe ventricular dysfunction and haemodynamic compromise, two months after transplantation. "
08/28/2006 - "Cellular transplantation has emerged as a novel therapeutic option for treatment of ventricular dysfunction. "
07/04/2006 - "Cellular transplantation is emerging as a promising strategy for the treatment of postinfarction ventricular dysfunction. "
|5.||Drug Therapy (Chemotherapy)
06/01/2008 - "Other clinical applications of BNP, such as screening for asymptomatic ventricular dysfunction, establishing the prognosis or guiding the titration of drug therapy, are under investigation and have not yet been sufficiently validated for widespread clinical use. "
04/01/1999 - "Intraaortic balloon counterpulsation is frequently used in patients experiencing severe ventricular dysfunction following maximal drug therapy. "
07/01/1991 - "A case of severe right-sided ventricular dysfunction shortly after an aggressive cycle of chemotherapy for metastatic colon carcinoma is presented."
07/01/1996 - "Anthracycline-induced cardiotoxicity limits effective cancer chemotherapy by causing early cardiomyopathy, and it can produce late-onset ventricular dysfunction years after treatment has ceased. "
09/12/2006 - "Other clinical uses of the natriuretic peptides, such as screening for asymptomatic ventricular dysfunction, establishing prognosis or guiding titration of drug therapy, are under investigation but have not yet sufficiently been validated for widespread clinical use."